Alpine immune sciences, inc. (ALPN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Collaboration revenue

1,740

705

1,731

2,950

-

-

-

Collaboration revenue

-

-

-

-

492

-

-

Revenue

-

-

-

-

-

0

-

Operating expenses:
Research and development

35,847

28,970

10,626

2,989

422

12,200

13,136

General and administrative

9,467

8,362

6,079

1,149

441

2,287

2,141

Loss on sale of intangible asset

0

-1,203

0

0

-

-

-

Total operating expenses

45,314

38,535

16,705

4,138

863

-

-

Loss from operations

-43,574

-37,830

-14,974

-1,188

-371

-14,487

-15,277

Other income (expense):
Business Combination, Bargain Purchase, Gain Recognized, Amount

0

0

6,601

0

-

-

-

Interest income

-

-

-

-

-

296

-

Interest and other income, net

-

-

-

-

-

-

10

Interest expense

338

319

152

0

-

845

931

Interest income

1,248

1,296

542

-

-

-

-

Other income

812

0

0

-

-

-

-

Interest income

-

-

-

22

2

-

-

Loss before taxes

-41,852

-36,853

-7,983

-1,166

-369

-

-

Income Tax Expense (Benefit)

0

-366

-200

66

-

-

-

Net loss

-

-

-

-

-

-

-16,198

Net loss

-41,852

-36,487

-7,783

-1,232

-369

-15,036

-16,198

Comprehensive income (loss):
Unrealized (loss) gain on investments

29

46

-59

0

-

-

-

Unrealized loss on foreign currency translation

-6

0

0

-

-

-

-

Gain on extinguishment of convertible debt as a capital transaction

-

-

-

-

-

378

-

Net loss attributable to common stockholders

-

-

-

-

-

-14,658

-

Comprehensive loss

-41,829

-36,441

-7,842

-1,232

-369

-14,658

-16,198

Weighted-average shares used to compute basic and diluted net loss per share (in shares)

18,358

13,849

6,481

564

496

723

0

Basic and diluted net loss per share (in dollars per share)

-2.28

-2.63

-1.20

-2.18

-0.74

-20.27

-104.50